MOB Stock Overview
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Moberg Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 11.23 |
| 52 Week High | SEK 40.90 |
| 52 Week Low | SEK 6.15 |
| Beta | 0.95 |
| 11 Month Change | -64.80% |
| 3 Month Change | -56.27% |
| 1 Year Change | 41.26% |
| 33 Year Change | -82.34% |
| 5 Year Change | -98.26% |
| Change since IPO | -96.09% |
Recent News & Updates
Recent updates
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Sep 14
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 08Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Nov 16Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?
Jan 17Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares
Dec 03
Shareholder Returns
| MOB | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -61.6% | 0.6% | 2.5% |
| 1Y | 41.3% | 78.2% | 19.4% |
Return vs Industry: MOB underperformed the Swedish Pharmaceuticals industry which returned 81.5% over the past year.
Return vs Market: MOB exceeded the Swedish Market which returned 18.3% over the past year.
Price Volatility
| MOB volatility | |
|---|---|
| MOB Average Weekly Movement | 19.7% |
| Pharmaceuticals Industry Average Movement | 8.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: MOB's share price has been volatile over the past 3 months.
Volatility Over Time: MOB's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 9 | Anna Ljung | www.mobergpharma.se |
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.
Moberg Pharma AB (publ) Fundamentals Summary
| MOB fundamental statistics | |
|---|---|
| Market cap | SEK 524.37m |
| Earnings (TTM) | -SEK 22.75m |
| Revenue (TTM) | SEK 4.93m |
106.4x
P/S Ratio-23.0x
P/E RatioIs MOB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOB income statement (TTM) | |
|---|---|
| Revenue | SEK 4.93m |
| Cost of Revenue | SEK 1.72m |
| Gross Profit | SEK 3.21m |
| Other Expenses | SEK 25.97m |
| Earnings | -SEK 22.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 65.19% |
| Net Profit Margin | -461.64% |
| Debt/Equity Ratio | 0% |
How did MOB perform over the long term?
See historical performance and comparison